News
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Melior Is Recognized as CRO of the Year by Life Sciences Review
Life Sciences Review annually selects 10 preeminent CROs and has chosen Melior Discovery as the top CRO in 2023
The editors recognized Melior’s unique capabilities in the pre-clinical in vivo pharmacology space with its theraTRACE offering, its breadth of model offerings, and boutique client interaction experience
SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Venatorx Pharmaceuticals Expands Senior Leadership Team
Key Hires in CMC/Technical Operations, Business Development, and Finance
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease
IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024
Vittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
No Clinical Safety or Efficacy Issues Identified
No Requirement for Further Clinical Data or Trials
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint
Composite Efficacy Sustained at Late Follow-up Visit
Safety Profile Consistent with Meropenem